Aganepag isopropyl (AGN-210961) is an EP2 agonist[1][2].
Aganepag isopropyl (AGN-210961) is an EP2 agonist[1][2].
[1]. Impagnatiello F, et al. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2019;176(8):1079-1089.
[2]. Matsou A, et al. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma. Expert Opin Investig Drugs. 2018;27(10):777-785.
















